Our Pricing

Mounjaro vs Wegovy: Which Weight Loss Injection Works Best for UK Patients?

When comparing Mounjaro vs Wegovy, UK patients often ask which injectable weight loss treatment delivers better results. Both medications are highly effective GLP-1 receptor agonists licensed by the MHRA for chronic weight management, but they work through different mechanisms and show distinct efficacy profiles in clinical trials. As a UK-registered pharmacy with thousands of weight loss consultations completed, we've seen both treatments transform patient outcomes when prescribed appropriately.

Key Differences Between Mounjaro vs Wegovy for Weight Loss

The fundamental difference in the Mounjaro vs Wegovy debate lies in their active ingredients and receptor mechanisms. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist, whilst Wegovy contains semaglutide, a selective GLP-1 receptor agonist [1]. This dual-action mechanism means Mounjaro targets two incretin pathways simultaneously, potentially offering enhanced metabolic benefits beyond weight reduction alone.

Clinical trial data demonstrates that Mounjaro users achieved average weight loss of 15-22.5% of initial body weight across the SURPASS clinical programme, compared to Wegovy's 10.9-15% average weight reduction in the STEP trials [2]. Both medications work by reducing appetite, slowing gastric emptying, and improving insulin sensitivity, but the additional GIP receptor activation in Mounjaro may explain its superior weight loss outcomes in head-to-head comparisons. All prescription treatments require clinical assessment by a UK-registered prescriber before dispensing.

Mounjaro vs Wegovy: Clinical Trial Evidence and Efficacy

When evaluating Mounjaro vs Wegovy through rigorous clinical evidence, the SURPASS-2 trial provides direct comparative data. Participants taking tirzepatide 15mg lost an average of 12.4kg compared to 6.2kg with semaglutide 1mg over 40 weeks [3]. The STEP 1 trial showed Wegovy users achieved mean weight loss of 14.9% at 68 weeks, whilst SURPASS-1 demonstrated Mounjaro users lost up to 22.5% at the highest 15mg dose [4].

Both treatments show sustained efficacy when combined with lifestyle modifications including a reduced-calorie diet and increased physical activity. In our clinical experience across thousands of UK consultations, patients on either medication report significant appetite suppression within the first fortnight of treatment. The choice between Mounjaro vs Wegovy often depends on individual response, tolerability, and the degree of weight loss required to achieve health goals.

Real-World Effectiveness in UK Patients

Beyond controlled trials, real-world evidence from UK prescribing data suggests both Mounjaro and Wegovy deliver clinically meaningful weight loss when prescribed appropriately. Our superintendent pharmacist Tarun Kumar notes that patient adherence remains the strongest predictor of success with either treatment, with weekly injection routines proving manageable for most individuals. Subject to prescriber approval, both medications can be continued long-term for weight maintenance after initial reduction phases.

Side Effects: Mounjaro vs Wegovy Safety Profiles

The side effect profiles when comparing Mounjaro vs Wegovy show considerable overlap, as both are incretin-based therapies. The most common adverse effects include nausea (reported in 20-44% of users), diarrhoea, constipation, vomiting, and abdominal discomfort [5]. These gastrointestinal symptoms typically occur during dose escalation phases and diminish over 4-8 weeks as tolerance develops.

Mounjaro users report slightly higher rates of nausea at equivalent weight loss levels compared to Wegovy, likely due to its dual receptor mechanism producing more pronounced effects on gastric motility. However, serious adverse events remain rare with both treatments. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease. All patients require baseline assessment and ongoing monitoring by UK healthcare professionals.

Managing Common Side Effects

In our experience supporting UK patients through Mounjaro vs Wegovy treatment journeys, simple strategies significantly reduce side effect burden. Taking injections after meals rather than on an empty stomach, staying well-hydrated, eating smaller frequent meals, and avoiding high-fat foods all improve tolerability. Most patients find symptoms manageable and consider them acceptable trade-offs for the weight loss achieved.

Dosing Schedules: Mounjaro vs Wegovy Administration

Both Mounjaro vs Wegovy require once-weekly subcutaneous injections, typically administered in the abdomen, thigh, or upper arm. Wegovy follows a fixed escalation schedule starting at 0.25mg weekly, increasing monthly to a maintenance dose of 2.4mg [6]. Mounjaro begins at 2.5mg weekly and can be titrated up to 15mg based on individual response and tolerability, offering more flexible dosing options.

The injection devices differ slightly: Mounjaro uses a KwikPen auto-injector whilst Wegovy employs a pre-filled FlexTouch pen. Both systems are designed for home self-administration after initial training. Patients should rotate injection sites weekly and maintain consistent injection timing for optimal therapeutic levels. Missing occasional doses is generally well-tolerated, but consistency improves outcomes.

Cost Comparison: Mounjaro vs Wegovy UK Pricing

When evaluating Mounjaro vs Wegovy from a cost perspective, UK pricing varies significantly by dose and supplier. At Cured Pharmacy, Wegovy starts from £124.99 whilst Mounjaro begins at £124.99, both subject to clinical assessment and prescriber approval. New patients can access £20 off their first order using code Weightlossnew, making treatment more accessible for those beginning their weight loss journey.

The price difference reflects Mounjaro's newer market entry and dual-receptor formulation, though both represent considerable monthly investments. Many patients find the superior weight loss outcomes with Mounjaro justify the additional cost, whilst others achieve their goals successfully with Wegovy at a lower price point. Neither medication is routinely available on NHS prescription for weight management alone, making private online pharmacies like Cured Pharmacy the primary access route for most UK patients. All pricing is transparent and displayed before consultation, with no hidden fees.

Long-Term Treatment Costs

When comparing Mounjaro vs Wegovy over extended treatment periods, patients should budget for 6-12 months of therapy to achieve and consolidate weight loss goals. Maintenance doses can sometimes be reduced after initial weight reduction, potentially lowering ongoing costs. Our clinical team provides personalised guidance on optimal treatment duration during online consultations.

Which Should You Choose: Mounjaro vs Wegovy Decision Guide

Deciding between Mounjaro vs Wegovy depends on multiple individual factors including weight loss goals, budget, previous treatment response, and medical history. Patients requiring greater weight reduction (>20% body weight) may benefit more from Mounjaro's enhanced efficacy, whilst those seeking effective results at lower cost often succeed with Wegovy. Both medications require commitment to lifestyle changes for optimal outcomes.

During your free online consultation at Cured Pharmacy, our UK-registered prescribers assess your BMI, weight loss history, comorbidities, current medications, and personal preferences to recommend the most appropriate option. The consultation takes under 3 minutes to complete, and approved prescriptions are dispensed from our UK-registered pharmacy with discreet next-day delivery. Both Mounjaro and Wegovy represent evidence-based, MHRA-licensed treatments that have helped thousands of UK patients achieve sustainable weight loss when used as part of comprehensive weight management programmes [7].

Scientific References

1. Frías, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Frías, J. P., et al. (2021). Efficacy and safety of tirzepatide versus semaglutide: SURPASS-2 trial results. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
4. Wilding, J. P., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro and Wegovy: Summary of Product Characteristics. MHRA UK. [accessed 15 August 2026]
6. Electronic Medicines Compendium. (2023). Wegovy 2.4mg solution for injection in pre-filled pen. Datapharm Ltd. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide and tirzepatide for managing overweight and obesity. NICE guideline TA875. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.